{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T08:11:22Z","timestamp":1765872682301,"version":"3.48.0"},"reference-count":40,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"unspecified","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Yale University-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI) Scholars Program"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,10,2]]},"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare the premarket and postmarket evidence of safety and efficacy of direct oral anticoagulants approved for stroke prevention in atrial fibrillation patients across four major regulatory agencies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Cross-sectional.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>European Medicines Association (EMA), US Food and Drug Administration (FDA), Health Canada and Australian Therapeutic Goods Administration (TGA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Apixaban, dabigatran, edoxaban and rivaroxaban marketing authorisations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome measures<\/jats:title>\n                    <jats:p>Concordance among regulatory agencies with respect to (1) premarket evidence used to establish efficacy and safety and (2) postmarket safety boxed warnings and postmarketing study requirements.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Apixaban, dabigatran and rivaroxaban were approved by each of the four regulatory agencies; edoxaban was only not approved by TGA. For premarket efficacy evidence, there was concordance across all agencies in terms of phase 3 trials for three (75%) drugs, sample size for three (75%) drugs, primary endpoints for four (100%) drugs, numerical results for three (75%) drugs, agency interpretation of results for four (100%) drugs and number of phase 2 trials for three (75%) drugs. For the premarket safety evidence, there was concordance across all agencies in terms of phase 3 trials for three (75%) drugs, sample size for two (50%) drugs, primary endpoints for four (100%) drugs, numerical results for three (75%) drugs, agency interpretation of results for three (75%) drugs and number of phase 2 trials for zero (0%) drugs. For postmarket safety information, FDA was the only agency that issued boxed warnings (for three (75%) drugs). Additionally, EMA and TGA required postmarketing studies (for four (100%) and two (50%) drugs, respectively), while FDA and Health Canada did not have any postmarketing requirements.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There was a high degree of concordance in the phase 3 trial premarket evidence used to establish efficacy and safety of direct oral anticoagulant approvals across four major regulatory agencies, but discordance in the phase 2 trial premarket evidence used, as well as in postmarket safety boxed warnings and postmarketing study requirements. These discrepancies highlight opportunities for further harmonisation in the evaluation and regulation of medical products globally.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-090376","type":"journal-article","created":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T07:55:57Z","timestamp":1729929357000},"page":"e090376","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Direct oral anticoagulant approvals by four major regulatory agencies: a cross-sectional analysis of premarket and postmarket evidence"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct00496769","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00412984","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00403767","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00403767","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00403767","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00494871","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9347-494X","authenticated-orcid":false,"given":"Maryam","family":"Mooghali","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianna","family":"Zhou","sequence":"additional","affiliation":[{"name":"Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph S","family":"Ross","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA"},{"name":"Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut, USA"},{"name":"Center for Outcomes Research and Evaluation, Yale New Haven Health System, New Haven, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,10,26]]},"reference":[{"key":"2025121600093768000_14.10.e090376.1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.019893"},{"key":"2025121600093768000_14.10.e090376.2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.4369"},{"key":"2025121600093768000_14.10.e090376.3","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017559","article-title":"Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges","volume":"9","author":"Chen","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2025121600093768000_14.10.e090376.4","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2158"},{"key":"2025121600093768000_14.10.e090376.5","unstructured":"U.S. Food and Drug Administration . Development & Approval Process | Drugs, Available: https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs#:~:text=A%20team%20of%20CDER%20physicians,drug%20is%20approved%20for%20sale"},{"key":"2025121600093768000_14.10.e090376.6","unstructured":"European Medicines Agency . Authorisation of Medicines, Available: https:\/\/www.ema.europa.eu\/en\/about-us\/what-we-do\/authorisation-medicines"},{"key":"2025121600093768000_14.10.e090376.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1200223"},{"key":"2025121600093768000_14.10.e090376.8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0286802","article-title":"New drug submissions in Canada and a comparison with the Food and Drug Administration and the European Medicines Agency: Cross-sectional analysis","volume":"18","author":"Lexchin","year":"2023","journal-title":"PLoS One"},{"key":"2025121600093768000_14.10.e090376.9","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jacbts.2016.06.003","article-title":"Drugs and Devices: Comparison of European and U.S. Approval Processes","volume":"1","author":"Van Norman","year":"2016","journal-title":"JACC Basic Transl Sci"},{"key":"2025121600093768000_14.10.e090376.10","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13879","article-title":"Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States: A comparative study of accelerated approvals","volume":"17","author":"Hakariya","year":"2024","journal-title":"Clin Transl Sci"},{"key":"2025121600093768000_14.10.e090376.11","doi-asserted-by":"crossref","first-page":"e1522","DOI":"10.1200\/OP.21.00909","article-title":"Clinical Benefit and Expedited Approval of Cancer Drugs in the United States","volume":"18","author":"Hwang","year":"2022","journal-title":"JCO Oncol Pract Sep"},{"key":"2025121600093768000_14.10.e090376.12","unstructured":"Food and Drug Administration . International regulatory harmonization. n.d. Available: https:\/\/www.fda.gov\/drugs\/cder-international-program\/international-regulatory-harmonization"},{"key":"2025121600093768000_14.10.e090376.13","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.drudis.2016.02.016","article-title":"Matched analysis on orphan drug designations and approvals: cross regional analysis in the United States, the European Union, and Japan","volume":"21","author":"Murakami","year":"2016","journal-title":"Drug Discov Today"},{"key":"2025121600093768000_14.10.e090376.14","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00228-018-2431-7","article-title":"A comparison of new drugs approved by the FDA, the EMA, and Swissmedic: an assessment of the international harmonization of drugs","volume":"74","author":"Zeukeng","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"key":"2025121600093768000_14.10.e090376.15","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jclinepi.2021.10.027","article-title":"Clinical trials were missing from regulatory documents of extended-release methylphenidate for ADHD in adults: a case study of public documents","volume":"143","author":"Boesen","year":"2022","journal-title":"J Clin Epidemiol"},{"key":"2025121600093768000_14.10.e090376.16","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1177\/2168479018764660","article-title":"A Comparative Review of Marketing Authorization Decisions in Switzerland, the EU, and the USA","volume":"53","author":"Dalla Torre Di Sanguinetto","year":"2019","journal-title":"Ther Innov Regul Sci"},{"key":"2025121600093768000_14.10.e090376.17","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1565"},{"key":"2025121600093768000_14.10.e090376.18","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.16183","article-title":"Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019","volume":"5","author":"Lythgoe","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025121600093768000_14.10.e090376.19","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-014582","article-title":"Assessing the potential clinical impact of reciprocal drug approval legislation on access to novel therapeutics in the USA: a cohort study","volume":"7","author":"Larochelle","year":"2017","journal-title":"BMJ Open"},{"key":"2025121600093768000_14.10.e090376.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2014.07.013"},{"key":"2025121600093768000_14.10.e090376.21","unstructured":"European Medicines Agency . Medicines. n.d. Available: https:\/\/www.ema.europa.eu\/en\/medicines"},{"key":"2025121600093768000_14.10.e090376.22","unstructured":"U.S. Food and DrugAdministration . Drugs@FDA: FDA-Approved Drugs, Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm"},{"key":"2025121600093768000_14.10.e090376.23","unstructured":"Government of Canada . Drug Product Database: Access the database, Available: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/drug-product-database.html"},{"key":"2025121600093768000_14.10.e090376.24","unstructured":"Therapeutic Goods Administration . Australian Public Assessment Reports (AusPAR), Available: https:\/\/www.tga.gov.au\/resources\/auspar"},{"key":"2025121600093768000_14.10.e090376.25","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.45847","article-title":"Comparison of Clinical Study Results Reported in medRxiv Preprints vs Peer-reviewed Journal Articles","volume":"5","author":"Janda","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025121600093768000_14.10.e090376.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa065779"},{"key":"2025121600093768000_14.10.e090376.27","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-018-2957-0","article-title":"Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study","volume":"19","author":"Zou","year":"2018","journal-title":"Trials"},{"key":"2025121600093768000_14.10.e090376.28","unstructured":"Government of Canada . Guidance document: Product Monograph, Available: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/applications-submissions\/guidance-documents\/product-monograph\/guidance-document-product-monograph-2020.html"},{"key":"2025121600093768000_14.10.e090376.29","unstructured":"U.S. Food and DrugAdministration . Guidance for Industry: Warnings and Precautions, Contraindications, and Boxed Warning Sections of Labeling for Human Prescription Drug and Biological Products \u2014 Content and Format, Available: https:\/\/www.fda.gov\/media\/71866\/download"},{"key":"2025121600093768000_14.10.e090376.30","unstructured":"Department of Health and Aged Care . Therapeutic Goods Administration (TGA), Available: https:\/\/www.tga.gov.au\/resources\/resource\/guidance\/boxed-warning-guidance"},{"key":"2025121600093768000_14.10.e090376.31","unstructured":"ICH Harmonised Guideline . Revision of M4E guideline on enhancing the format and structure of benefit-risk information in ICH efficacy M4E(R2), Available: https:\/\/database.ich.org\/sites\/default\/files\/M4E_R2__Guideline.pdf"},{"key":"2025121600093768000_14.10.e090376.32","unstructured":"Electronic Code of Federal Regulation . Title 21, chapter 1, subchapter d, part 314, subpart B, \u00a7314.50, 2017. Available: https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-D\/part-314\/subpart-B\/section-314.50"},{"key":"2025121600093768000_14.10.e090376.33","unstructured":"Health Canada . n.d. Submission Certificate for a New Drug Submission (NDS), Supplement to a New Drug Submission (SNDS), Supplement to an Abbreviated New Drug Submission (SANDS), Abbreviated New Drug Submission (ANDS), or Notifiable Change (NC)."},{"key":"2025121600093768000_14.10.e090376.34","unstructured":"European Medicines Agency . ICH M4E Common technical document for the registration of pharmaceuticals for human use - efficacy - Scientific guideline, Available: https:\/\/www.ema.europa.eu\/en\/ich-m4e-common-technical-document-registration-pharmaceuticals-human-use-efficacy-scientific"},{"key":"2025121600093768000_14.10.e090376.35","unstructured":"Therapeutic Goods Administration . n.d. Appendix A - Specific mandatory requirements."},{"key":"2025121600093768000_14.10.e090376.36","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.680","article-title":"Regulatory post-market drug safety advisories on cardiac harm: A comparison of four national regulatory agencies","volume":"8","author":"Hooimeyer","year":"2020","journal-title":"Pharmacol Res Perspect"},{"key":"2025121600093768000_14.10.e090376.37","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamainternmed.2019.0294","article-title":"Comparative Analysis of Medicines Safety Advisories Released by Australia, Canada, the United States, and the United Kingdom","volume":"179","author":"Perry","year":"2019","journal-title":"JAMA Intern Med"},{"key":"2025121600093768000_14.10.e090376.38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109100","article-title":"Inconsistencies among European Union pharmaceutical regulator safety communications: a cross-country comparison","volume":"9","author":"Zeitoun","year":"2014","journal-title":"PLoS One"},{"key":"2025121600093768000_14.10.e090376.39","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1111\/bcp.14749","article-title":"Rationales of delay and difference in regulatory review by Japan, the USA and Europe among new drugs first approved in Japan","volume":"87","author":"Tanaka","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"2025121600093768000_14.10.e090376.40","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.k2031","article-title":"Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis","volume":"361","author":"Wallach","year":"2018","journal-title":"BMJ"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-090376","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T08:09:48Z","timestamp":1765872588000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-090376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":40,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10,26]]},"published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1136\/bmjopen-2024-090376"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-090376","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2024,10]]}}}